Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model ; volume:4 ; number:1 ; day:3 ; month:10 ; year:2014 ; pages:1-10 ; date:12.2014
EJNMMI Research ; 4, Heft 1 (3.10.2014), 1-10, 12.2014
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-014-0054-2
- URN
-
urn:nbn:de:101:1-2021082321205055138590
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lindenblatt, Dennis
- Fischer, Eliane
- Cohrs, Susan
- Schibli, Roger
- Grünberg, Jürgen
- SpringerLink (Online service)
Other Objects (12)
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models
Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
DIAPH1 faciliates paclitaxel-mediated cytotoxicity of ovarian cancer cells
TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Hyperacute xenograft rejection
Inhibition of Drp1 orchestrates the responsiveness of breast cancer cells to paclitaxel but insignificantly relieves paclitaxel-related ovarian damage in mice
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models
Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
DIAPH1 faciliates paclitaxel-mediated cytotoxicity of ovarian cancer cells
TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Hyperacute xenograft rejection
Inhibition of Drp1 orchestrates the responsiveness of breast cancer cells to paclitaxel but insignificantly relieves paclitaxel-related ovarian damage in mice
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models
Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
DIAPH1 faciliates paclitaxel-mediated cytotoxicity of ovarian cancer cells
TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer
Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Hyperacute xenograft rejection